Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 6/20 | 0.44 |
| ▸ | ITGB1 | P05556 | 12/20 | 0.43 |
| ▸ | ITGA4 | P13612 | 8/20 | 0.43 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.43 |
| ▸ | ITGAV | P06756 | 3/20 | 0.38 |
| ▸ | ITGA5 | P08648 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3852356 | 0.91 | CACNA1B (0.45) | CACNA1BITGB1ITGA4ITGB7ITGAV | |
| SCHEMBL5608873 | 0.86 | ITGB1 (0.44) | CACNA1BITGB1ITGA4ITGB7ITGAV | |
| SCHEMBL3855808 | 0.86 | ITGA4 (0.52) | CACNA1BITGB1ITGA4ITGB7ITGA5 | |
| SCHEMBL3851264 | 0.85 | CACNA1B (0.51) | CACNA1BITGB1ITGA4ITGB7ITGA5 | |
| SCHEMBL3855039 | 0.84 | CACNA1B (0.46) | CACNA1BITGB1ITGA4ITGB7ITGA5 | |
| SCHEMBL3855409 | 0.84 | ITGB1 (0.46) | CACNA1BITGB1ITGA4ITGB7ITGAV | |
| SCHEMBL4451846 | 0.83 | KDM4E (0.43) | CACNA1BITGB1ITGA4ITGB7 | |
| SCHEMBL3855049 | 0.83 | CACNA1B (0.46) | CACNA1BITGB1ITGA4ITGB7ITGAV | |
| SCHEMBL12317079 | 0.83 | ITGB1 (0.48) | CACNA1BITGB1ITGA4ITGB7ITGAV | |
| SCHEMBL3855802 | 0.83 | CACNA1B (0.46) | CACNA1BITGB1ITGA4ITGB7ITGA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6900179-B2 | Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. | 2005-05-31 | — | — | US | disclosed |
| US-20020193312-A1 | Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. | 2002-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193312-A1 | Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, L1CAM | CACNA1B 383/4885ITGB1 64/4885ITGA4 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.